Alexion Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes various therapeutic products. The company offers ULTOMIRIS (ALXN1210/ravulizumab-cwvz), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and Soliris (eculizumab), a monoclonal antibody for the treatment of PNH, atypical hemolytic uremic syndrome (aHUS), and generalized myasthenia gravis. It also provides Strensiq (asfotase alfa), a targeted enzyme replacement therapy for patients with hypophosphatasia; and Kanuma (sebelipase alfa) for the treatment of patients with lysosomal acid lipase deficiency. In addition, the company conducts Phase III clinical trials for ALXN 1210 (IV) that is in Phase III clinical trials for the treatment of PNH and aHUS; ALXN1210 (Subcutaneous), which is in Phase I for PNH and aHUS; and Soliris (eculizumab) for the treatment of myasthenia gravis and neuromyelitis optica spectrum disorder. Further, it develops ALXN1840 (WTX101) that is in Phase III clinical trials for the treatment of Wilson disease; and ALXN1830 (SYNT001), which is in Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company serves distributors, pharmacies, hospitals, hospital buying groups, and other healthcare providers in the United States, Europe, the Asia Pacific, and internationally. Alexion Pharmaceuticals, Inc. has collaboration and license agreement with Halozyme Therapeutics, Inc. to use drug-delivery technology in the development of subcutaneous formulations for its portfolio of products; collaboration with Dicerna Pharmaceuticals, Inc. to discover and develop RNAi therapies for complement-mediated diseases, as well as with Zealand Pharma A/S; strategic agreement with Caelum Biosciences, Inc. to advance the development of CAEL-101 for light chain (AL) amyloidosis; and partnership with Affibody AB. The company was founded in 1992 and is headquartered in Boston, Massachusetts.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Phone475-230-2596
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$4.13 billion
Profitability
Miscellaneous
Employees2,656
Next Earnings Date4/25/2019 (Confirmed)
OptionableOptionable
Alexion Pharmaceuticals (NASDAQ:ALXN) Frequently Asked Questions
What is Alexion Pharmaceuticals' stock symbol?
Alexion Pharmaceuticals trades on the NASDAQ under the ticker symbol "ALXN."
How were Alexion Pharmaceuticals' earnings last quarter?
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) released its quarterly earnings results on Monday, February, 4th. The biopharmaceutical company reported $2.14 EPS for the quarter, topping the Zacks' consensus estimate of $1.60 by $0.54. The biopharmaceutical company had revenue of $1.13 billion for the quarter, compared to analyst estimates of $1.06 billion. Alexion Pharmaceuticals had a return on equity of 18.15% and a net margin of 1.88%. Alexion Pharmaceuticals's revenue for the quarter was up 24.1% on a year-over-year basis. During the same period in the prior year, the company earned $1.48 EPS. View Alexion Pharmaceuticals' Earnings History.
When is Alexion Pharmaceuticals' next earnings date?
What guidance has Alexion Pharmaceuticals issued on next quarter's earnings?
Alexion Pharmaceuticals issued an update on its FY19 earnings guidance on Monday, February, 4th. The company provided earnings per share guidance of $9.10-9.30 for the period, compared to the Thomson Reuters consensus EPS estimate of $8.80. The company issued revenue guidance of $4.625-4.7 billion, compared to the consensus revenue estimate of $4.75 billion.Alexion Pharmaceuticals also updated its FY 2019 guidance to $9.10-9.30 EPS.
What price target have analysts set for ALXN?
15 brokers have issued 12-month target prices for Alexion Pharmaceuticals' shares. Their forecasts range from $123.00 to $190.00. On average, they anticipate Alexion Pharmaceuticals' share price to reach $163.9333 in the next twelve months. This suggests a possible upside of 30.8% from the stock's current price. View Analyst Price Targets for Alexion Pharmaceuticals.
What is the consensus analysts' recommendation for Alexion Pharmaceuticals?
15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alexion Pharmaceuticals in the last year. There are currently 3 hold ratings and 12 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Alexion Pharmaceuticals.
Has Alexion Pharmaceuticals been receiving favorable news coverage?
News coverage about ALXN stock has trended somewhat positive this week, InfoTrie Sentiment reports. InfoTrie scores the sentiment of press coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Alexion Pharmaceuticals earned a coverage optimism score of 0.7 on InfoTrie's scale. They also gave news headlines about the biopharmaceutical company a news buzz of 3.0 out of 10, meaning that recent press coverage is unlikely to have an effect on the stock's share price in the near term.
Who are some of Alexion Pharmaceuticals' key competitors?
Some companies that are related to Alexion Pharmaceuticals include Sanofi (SNY), GlaxoSmithKline (GSK), AstraZeneca (AZN), Bristol-Myers Squibb (BMY), Celgene (CELG), Bayer (BAYRY), Shire (SHPG), Allergan (AGN), Zoetis (ZTS), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Shiseido (SSDOY), Takeda Pharmaceutical (TKPYY), Takeda Pharmaceutical (TAK) and ASTELLAS PHARMA/ADR (ALPMY).
What other stocks do shareholders of Alexion Pharmaceuticals own?
Who are Alexion Pharmaceuticals' key executives?
Alexion Pharmaceuticals' management team includes the folowing people:
- Dr. Ludwig N. Hantson, CEO & Director (Age 56)
- Mr. Paul J. Clancy, Exec. VP & CFO (Age 57)
- Ms. Anne-Marie Law, Exec. VP and Chief Patient & Employee Experience Officer (Age 52)
- Mr. Brian M. Goff, Exec. VP & Chief Commercial Officer (Age 50)
- Dr. John J. Orloff, Exec. VP and Head of R&D (Age 62)
Who are Alexion Pharmaceuticals' major shareholders?
Alexion Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Calamos Advisors LLC (0.31%), Factory Mutual Insurance Co. (0.24%), Peregrine Capital Management LLC (0.07%), Rhenman & Partners Asset Management AB (0.06%), Vigilant Capital Management LLC (0.05%) and Retirement Systems of Alabama (0.05%). Company insiders that own Alexion Pharmaceuticals stock include Ann M Veneman, Bros Advisors Lp Baker, Christopher J Coughlin, Daniel Bazarko, Heidi L Wagner, Indrani Lall Franchini, John B Moriarty, John J Orloff, Julie O'neill, Ludwig Hantson and Paul J Clancy. View Institutional Ownership Trends for Alexion Pharmaceuticals.
Which institutional investors are selling Alexion Pharmaceuticals stock?
ALXN stock was sold by a variety of institutional investors in the last quarter, including Factory Mutual Insurance Co., Gateway Investment Advisers LLC, Rhenman & Partners Asset Management AB, Calamos Advisors LLC, Empire Life Investments Inc., Stralem & Co. Inc., State of Alaska Department of Revenue and Gradient Investments LLC. Company insiders that have sold Alexion Pharmaceuticals company stock in the last year include Daniel Bazarko, Indrani Lall Franchini, John J Orloff, Ludwig Hantson and Paul J Clancy. View Insider Buying and Selling for Alexion Pharmaceuticals.
Which institutional investors are buying Alexion Pharmaceuticals stock?
ALXN stock was purchased by a variety of institutional investors in the last quarter, including Pacer Advisors Inc., Meeder Asset Management Inc., DNB Asset Management AS, Landsberg Bennett & Dubbaneh LLC, Calamos Wealth Management LLC, Ingalls & Snyder LLC, Nisa Investment Advisors LLC and Juncture Wealth Strategies LLC. Company insiders that have bought Alexion Pharmaceuticals stock in the last two years include Bros Advisors Lp Baker, Christopher J Coughlin and Ludwig Hantson. View Insider Buying and Selling for Alexion Pharmaceuticals.
How do I buy shares of Alexion Pharmaceuticals?
Shares of ALXN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Alexion Pharmaceuticals' stock price today?
One share of ALXN stock can currently be purchased for approximately $125.33.
How big of a company is Alexion Pharmaceuticals?
Alexion Pharmaceuticals has a market capitalization of $28.01 billion and generates $4.13 billion in revenue each year. The biopharmaceutical company earns $77.59 million in net income (profit) each year or $7.09 on an earnings per share basis. Alexion Pharmaceuticals employs 2,656 workers across the globe.
What is Alexion Pharmaceuticals' official website?
How can I contact Alexion Pharmaceuticals?
Alexion Pharmaceuticals' mailing address is 121 SEAPORT BOULEVARD, BOSTON MA, 02210. The biopharmaceutical company can be reached via phone at 475-230-2596 or via email at [email protected]
MarketBeat Community Rating for Alexion Pharmaceuticals (NASDAQ ALXN)
MarketBeat's community ratings are surveys of what our community members think about Alexion Pharmaceuticals and other stocks. Vote "Outperform" if you believe ALXN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ALXN will underperform the S&P 500 over the long term. You may vote once every thirty days.
